Pharmalink reports positive Ph III data with PPS injection

Swedish drugmaker Pharmalink AB has reported positive results from a follow-on Phase III study of Xepol, its candidate for the treatment of post-polio syndrome. The late-stage data show the candidate is effective and well tolerated with no serious adverse events reported so far.

Involving 142 patients, the placebo-controlled, double-blind trial was designed to evaluate the efficacy and safety of Xepol in PPS, a neurological pain and weakness syndrome in patients that have survived poliovirus infection.

Endpoints studied were pain, walking ability and SF-36 scores, a common self-assessment scoring system that measures physical and psychological variables. All showed significant and clinically-meaningful results, according to the firm, which plans to present full data in a peer-reviewed journal.